FTFinancial Times·1hBusiness
score+0.60
GSK’s $10.6bn cancer deal will lead to more
Original
GSK’s $10.6bn cancer deal will lead to more
“Positive framing emphasizes strategic investment and growth momentum in pharmaceutical pipeline expansion.”
GSK’s $10.6bn cancer deal will lead to more
“Positive framing emphasizes strategic investment and growth momentum in pharmaceutical pipeline expansion.”
Two quick questions. 0 responses so far.
No comments yet. Be the first.